Moreover, PET studies showed increased dopaminergic and cholinergic activity in LRRK2 non-manifesting carriers compared to sporadic PD cases, possibly reflecting compensatory changes preceding the motor onset of PD (41, 42). The gene discussed is LRRK2; the disease is Parkinson disease.